Seom guidelines for the treatment of gastric cancer 2015. [guía clínica]
Por: Grávalos Castro, Cristina [Oncología Médica]
.
Colaborador(es): Servicio de Oncología Médica.
Tipo de material: 
ArtículoEditor: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015Descripción: 17(12):996-1004.Recursos en línea: Acceso libre | Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Guía clínica
|
PC17359 (Navegar estantería) | Disponible |
Formato Vancouver:
Martin Richard M, Custodio A, García Girón C, Grávalos C, Gómez C, Jiménez Fonseca P et al. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):996-1004.
PMID: 26691658
PMC4689778.
Contiene 70 referencias
Erratum in: Clin Transl Oncol. 2016 Apr;18(4):426.
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum-fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the first-line treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement.
No hay comentarios para este ejemplar.